Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Michael Greene who wrote (3793)	10/21/1999 5:25:00 PM
From: Biomaven	Respond to of 10280

Michael, Certainly could have been advanced spin on a bad or equivocal result(assuming he knows the outcome already, which isn't clear). Alternatively, maybe he was just being cautious. Peter

To: Michael Greene who wrote (3793)	10/21/1999 8:11:00 PM
From: rkrw	Read Replies (1) \| Respond to of 10280

I was at the conference as well. I think Southwell is taking a more cautious approach to his public statements. He made the company look foolish by endorsing heady and eye-popping earnings estimates amongst other things. This kind of tact doesn't go over well with institutional investors. I've seen a noticeable change in his public appearances since. He did state that the study looked very closely at side effects and they hope to garner label advantages via the phase IV. With a 700 or so patient study, at the least, the results should more adequately prove their side effect advantages. As they say, we shall see. Regarding Labopharm/Chirex. No mention. Sepracor no longer owns Chirex so no reason to mention them as its simply a contract mfg for them. He's mentioned Labopharm in other presentations, more in the context of when discussing additional follow on forms-syrup, tablets, mdi and so forth. He had 40 minutes to present and I have to say, he reviewed the 30 slides barely able to draw a breathe and went over his allotted time by a bit. They have a lot to talk about.